news
12-30-2012, 02:49 AM
After pricing its once-obscure drug, Acthar, in the stratosphere, Questcor gained many fans on Wall Street. But the company has also drawn some doubters.http://rss.nytimes.com/c/34625/f/642562/s/270b998e/mf.gif
More... (http://www.nytimes.com/2012/12/30/business/questcor-finds-profit-for-acthar-drug-at-28000-a-vial.html?partner=rss&emc=rss)
More... (http://www.nytimes.com/2012/12/30/business/questcor-finds-profit-for-acthar-drug-at-28000-a-vial.html?partner=rss&emc=rss)